These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 20957215)
1. Current and developing therapeutic agents in the treatment of Chagas disease. Apt W Drug Des Devel Ther; 2010 Sep; 4():243-53. PubMed ID: 20957215 [TBL] [Abstract][Full Text] [Related]
2. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846 [TBL] [Abstract][Full Text] [Related]
3. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. Gallerano RR; Sosa RR Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232 [TBL] [Abstract][Full Text] [Related]
4. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245 [TBL] [Abstract][Full Text] [Related]
5. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Coura JR; de Abreu LL; Willcox HP; Petana W Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337 [TBL] [Abstract][Full Text] [Related]
7. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients. Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602 [TBL] [Abstract][Full Text] [Related]
8. [Allopurinol in the treatment of chronic Chagas' disease]. Meirovich CI; Montrull HL; Gallerano RH; Sosa RR Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099 [No Abstract] [Full Text] [Related]
9. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034 [TBL] [Abstract][Full Text] [Related]
11. Current status of Chagas disease chemotherapy. Guedes PM; Silva GK; Gutierrez FR; Silva JS Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270 [TBL] [Abstract][Full Text] [Related]
12. [Nifurtimox, a bright future for treatment of Chagas disease]. Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868 [TBL] [Abstract][Full Text] [Related]
13. [Changes in parasitemia evaluated using the modified Strout method in patients with acute Chagas disease under treatment]. Castro C; Emanuel A Rev Soc Bras Med Trop; 1988; 21(4):177-80. PubMed ID: 3152133 [No Abstract] [Full Text] [Related]
14. Antitrypanosomal therapy for chronic Chagas' disease. Bern C N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649 [No Abstract] [Full Text] [Related]
15. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503 [TBL] [Abstract][Full Text] [Related]
16. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Gallerano RH; Marr JJ; Sosa RR Am J Trop Med Hyg; 1990 Aug; 43(2):159-66. PubMed ID: 2117857 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Sosa Estani S; Segura EL Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756 [No Abstract] [Full Text] [Related]
19. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113 [TBL] [Abstract][Full Text] [Related]